Close Menu

NEW YORK – While mass spectrometry has played a substantial role in research into the biology of SARS-CoV-2, it has been largely absent as a tool for diagnosing infections.

Some researchers and studies, suggest, though, that the technology could carve out a niche within the COVID-19 testing world, even as molecular assays and, to a growing extent, immunoassay-based rapid antigen testing, will likely continue to dominate the diagnostic scene.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.